- Home
- VSTM vs ORIC Comparison
VSTM vs ORIC Comparison
Compare VSTM & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- ORIC
- Stock Information
- Founded
- VSTM 2010
- ORIC 2014
- Country
- VSTM United States
- ORIC United States
- Employees
- VSTM N/A
- ORIC N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- ORIC Health Care
- Exchange
- VSTM Nasdaq
- ORIC Nasdaq
- Market Cap
- VSTM 359.9M
- ORIC 362.9M
- IPO Year
- VSTM 2012
- ORIC 2020
- Fundamental
- Price
- VSTM $7.17
- ORIC $5.08
- Analyst Decision
- VSTM Strong Buy
- ORIC Strong Buy
- Analyst Count
- VSTM 9
- ORIC 8
- Target Price
- VSTM $13.63
- ORIC $18.83
- AVG Volume (30 Days)
- VSTM 1.4M
- ORIC 630.2K
- Earning Date
- VSTM 05-20-2025
- ORIC 05-05-2025
- Dividend Yield
- VSTM N/A
- ORIC N/A
- EPS Growth
- VSTM N/A
- ORIC N/A
- EPS
- VSTM N/A
- ORIC N/A
- Revenue
- VSTM $10,000,000.00
- ORIC N/A
- Revenue This Year
- VSTM $7.68
- ORIC N/A
- Revenue Next Year
- VSTM $605.06
- ORIC N/A
- P/E Ratio
- VSTM N/A
- ORIC N/A
- Revenue Growth
- VSTM N/A
- ORIC N/A
- 52 Week Low
- VSTM $2.10
- ORIC $3.90
- 52 Week High
- VSTM $13.52
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- VSTM 57.92
- ORIC 44.71
- Support Level
- VSTM $6.35
- ORIC $4.52
- Resistance Level
- VSTM $8.00
- ORIC $5.83
- Average True Range (ATR)
- VSTM 0.67
- ORIC 0.52
- MACD
- VSTM 0.01
- ORIC 0.07
- Stochastic Oscillator
- VSTM 46.93
- ORIC 40.58
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.